MMV & PARTNER SYMPOSIA
Antimalarials – tackling P. falciparum resistance through the use of irresistible compounds (Symposium 26: Thursday, 19 October – 10:45 AM-12:00 PM)
Symposium organizer: Didier Leroy, MMV, Switzerland. Co-Chair: Dr Susan Wyllie, Dundee School of Life Science
- Reduced susceptibility of fresh Plasmodium falciparum isolates to lumefantrine in northern Uganda. Patrick Tumwebaze, Infectious Disease Research Collaboration, Kampala, Uganda
- Developing a pipeline of irresistible antimalarials. Dr Dider Leroy, MMV, Geneva, Switzerland
- Defining P. falciparum susceptibility to irresistible compounds using genetic crosses. Prof. David Fidock, Columbia University Medical Centre, USA
- Proteomic approaches to dissecting the mode of action of irresistible compounds. Dr Susan Wyllie, Dundee School of Life Sciences, Dundee, UK
Reimagining the continuum of care for severe malaria patients (Symposium 83: Friday, 20 October – 1:45-3:30 PM)
Symposium organizer: Hans Rietveld, MMV, Switzerland. Co-Chair: Christine Manyando, Tropical Diseases Research Centre, Ndola, Zambia
- Updated guidance for the responsible deployment of rectal artesunate as a pre-referral intervention. Olugbenga Mokuolu, Management Sciences for Health, USA
- An alternative pathway for severe malaria patients in remote areas “where there is no doctor” – reflections from DRC and Zambia. Christine Manyando, Tropical Diseases Research Centre, Ndola, Zambia
- New target product profile for antimalarials to address the needs of patients with severe malaria. Dr Jane Achan, Malaria Consortium, Uganda
- Country perspectives on the new WHO recommendation for Post-discharge Malaria Chemoprevention in patients with severe anemia. Titus Kwambai, CDC Kenya
Emerging data on how best to use primaquine and tafenoquine for the radical cure of P. vivax (Symposium 159: Sunday, 22 October – 8:00-9:45 AM)
Symposium organizer: Stephan Duparc, MMV, Switzerland. Co-Chair: Robert J. Commons, Menzies School of Health Research, Darwin, Australia
- Trade-off between short term hemolytic risk and long-term benefit of 8-aminoquinoline treatment. Megha Rajasekhar, The University of Melbourne, Carlton, Australia
- Is there a way to individualize P. vivax radical cure regimens? Methemoglobin as a marker of antirelapse efficacy. Ihsan Fadilah. Oxford University Clinical Research Unit Indonesia, Jakarta, Indonesia
- How in vitro and in vivo vivax malaria models can help us understand the outcome of past clinical studies with tafenoquine and design the next set of studies. Brice Campo, MMV, Geneva, Switzerland
- The Tafenoquine Roll-out STudy (TRuST): Real-world evidence on feasibility of providing appropriate P. vivax radical cure with tafenoquine or primaquine after G6PD testing in the Brazilian Amazon – final results from a study of over 6,000 patients. Marcus Vinícius Guimarães de Lacerda, Dr Heitor Vieira Dourado Tropical Medicine Foundation, Manaus, Brazil
Benefits and Challenges of WHO Chemoprevention Guidelines Giving Increased Autonomy for Decision-Making to Countries (Partner Symposium 61 – MMV & PSI: Friday, 20 October – 10:15 AM-12:00 PM)
BPMC forecast: Estimate the potential demand for PMC SP for a number of predefined scenarios. Celine Audibert, MMV
Effectiveness and efficacy of chemoprevention for children under five (Partner Symposium 132 – MMV & SMC Alliance: Saturday, 21 October – 12:45-2:30 PM)
ORAL PRESENTATION & POSTERS
Late breaker Abstract Oral Presentation LB-8379 (Friday, 20 October: 12:00-1:30 PM – Grand Hall J, Ballroom Level, East Tower)
Safety, tolerability, pharmacokinetics and antimalarial efficacy of a novel Plasmodium falciparum blood stage inhibitor MMV533: a first-in-human study and a volunteer infection study.
Posters (Friday, 20 & Saturday, 21 October – Poster Hall)
Poster 6093: A first-in-human (FIH) safety, tolerability and pharmacokinetics (PK) study of MMV367, a new candidate anti-malarial agent for acute uncomplicated malaria
Poster LB-8505: Cardiac safety of dihydroartemisinin-piperaquine and sulfadoxine pyrimethamine among pregnant women with and without asymptomatic parasitaema in Tanzania: results from an open-label, parallel-group, randomized phase II trial
Poster 6908: Combining SMC activities with catch-up immunization and community malaria case management in Guinea
Poster Session LB-8450: Research and policy making symbiosis in Thailand: tafenoquine operational feasibility study informing national policy adoption,
Poster Session LB-8511: Results of the Tafenoquine Rollout Sudy in Brazil - a real-world feasibility study of over 6,000 patients.
LUNCH & SIDE EVENT
SMC Alliance Networking Lunch (Thursday, 19 October - 12:00-2:00 PM – Columbian, Concourse Level, West Tower, Hyatt Regency Chicago). For more info, contact Abena Poku-Awuku
Expert Panel Workshop on Tafenoquine use with ACTs (Invite only)